Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 21 Researches
8.3
USERS' SCORE
Good
Based on 2 Reviews
8.1
Supplement Facts
Serving Size: 1 tbsp (15 ml)
Amount Per Serving
%DV
Calories
120
Total Fat
14 g
18%
Saturated Fat
2.5 g
13%
Polyunsaturated Fat
8 g
Monounsaturated Fat
2 g
Sodium
0 mg
0%
Total Carbohydrate
0 g
0%
Protein
0 g
Vitamin E
20 mg
130%
Top Medical Research Studies
9.5
We explored the impact of engineered mesenchymal stromal cells (MSCs) on liver disease, specifically focusing on their ability to manage inflammation caused by excessive neutrophil infiltration. With conditions like autoimmune disorders and liver diseases often worsened by this inflammation, we found a remarkable way to enhance the therapeutic properties of MSCs.
By modifying these cells with P-selectin and E-selectin targeting peptides, we created a system where engineered MSCs could effectively compete with neutrophils at the site of injury. This clever design allows the MSCs to more efficiently reach the damaged liver in a mouse model of acute liver failure.
Our findings showcase that these modified MSCs not only home to the liver effectively, but they also significantly curb unnecessary neutrophil activity. This one-two punch of reducing inflammation and utilizing the MSCs' inherent healing abilities leads to better treatment outcomes. Notably, we observed an increase in certain macrophages that help inhibit neutrophils, further suggesting a multi-faceted approach to therapy. Overall, we're excited about how this strategy opens new doors for MSC-based therapies in helping repair damaged tissues.
By modifying these cells with P-selectin and E-selectin targeting peptides, we created a system where engineered MSCs could effectively compete with neutrophils at the site of injury. This clever design allows the MSCs to more efficiently reach the damaged liver in a mouse model of acute liver failure.
Our findings showcase that these modified MSCs not only home to the liver effectively, but they also significantly curb unnecessary neutrophil activity. This one-two punch of reducing inflammation and utilizing the MSCs' inherent healing abilities leads to better treatment outcomes. Notably, we observed an increase in certain macrophages that help inhibit neutrophils, further suggesting a multi-faceted approach to therapy. Overall, we're excited about how this strategy opens new doors for MSC-based therapies in helping repair damaged tissues.
Read More
9
We investigated the effects of a daily dose of 300 mg vitamin E for treating metabolic dysfunction-associated steatohepatitis (MASH). In our study, 124 non-diabetic individuals were randomly assigned to either vitamin E or a placebo.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
The results showed that 29.3% of those on vitamin E had improvements in liver histology, compared to just 14.1% in the placebo group. While we saw significant benefits in liver conditions like steatosis and inflammation, 12 serious adverse events were reported, although they weren’t linked to the treatment.
Overall, our findings indicate that vitamin E may offer meaningful improvements in liver health for those with MASH.
Read More
9
We analyzed multiple clinical trials to understand how vitamin E impacts liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD).
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Our findings reveal that vitamin E significantly improves key liver markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), suggesting it may help reduce liver inflammation.
Additionally, vitamin E enhances liver histology by decreasing fat accumulation and inflammation. However, it does not appear to affect liver fibrosis.
Overall, vitamin E could be a valuable option for managing liver health in MASLD patients.
Read More
Most Useful Reviews
7.5
Taste and health benefits
9 people found this helpful
I bought this oil for salads, and it’s simply delightful! I didn’t expect it to be so tasty. I often change my salad oils, but this one is exceptionally pleasant. It sits lightly on my stomach and feels curative for my liver and pancreas. I'm keen to order it regularly. Compared to olive oil, which feels heavy, this oil is rich yet light. I can’t quite describe my feelings otherwise.
Read More
2
No benefits observed
Its smell is unpleasant, and the texture feels stinging on my liver, and I didn’t observe any benefits from it, even after two days of use.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 21 Researches
8.3
- All Researches
9.5
We explored the impact of engineered mesenchymal stromal cells (MSCs) on liver disease, specifically focusing on their ability to manage inflammation caused by excessive neutrophil infiltration. With conditions like autoimmune disorders and liver diseases often worsened by this inflammation, we found a remarkable way to enhance the therapeutic properties of MSCs.
By modifying these cells with P-selectin and E-selectin targeting peptides, we created a system where engineered MSCs could effectively compete with neutrophils at the site of injury. This clever design allows the MSCs to more efficiently reach the damaged liver in a mouse model of acute liver failure.
Our findings showcase that these modified MSCs not only home to the liver effectively, but they also significantly curb unnecessary neutrophil activity. This one-two punch of reducing inflammation and utilizing the MSCs' inherent healing abilities leads to better treatment outcomes. Notably, we observed an increase in certain macrophages that help inhibit neutrophils, further suggesting a multi-faceted approach to therapy. Overall, we're excited about how this strategy opens new doors for MSC-based therapies in helping repair damaged tissues.
By modifying these cells with P-selectin and E-selectin targeting peptides, we created a system where engineered MSCs could effectively compete with neutrophils at the site of injury. This clever design allows the MSCs to more efficiently reach the damaged liver in a mouse model of acute liver failure.
Our findings showcase that these modified MSCs not only home to the liver effectively, but they also significantly curb unnecessary neutrophil activity. This one-two punch of reducing inflammation and utilizing the MSCs' inherent healing abilities leads to better treatment outcomes. Notably, we observed an increase in certain macrophages that help inhibit neutrophils, further suggesting a multi-faceted approach to therapy. Overall, we're excited about how this strategy opens new doors for MSC-based therapies in helping repair damaged tissues.
Read More
9.5
We explored the potential of liver transplantation as a definitive treatment for patients suffering from homozygous protein C deficiency, a serious disorder typically diagnosed in infancy. This condition leads to severe clotting issues and can result in life-threatening complications, such as purpura fulminans.
Our focus was on an eight-year-old girl who had struggled with this deficiency since birth, enduring various treatments that failed to improve her health significantly. Despite receiving fresh frozen plasma transfusions and anticoagulants, she continued to experience severe complications and a poor quality of life.
Upon receiving care in the United Arab Emirates, she was placed on the national transplant waiting list for a liver transplant, which eventually took place successfully. Notably, after the surgery, her protein C activity normalized, and she did not experience any thrombotic events.
This case highlights that for children with homozygous protein C deficiency, particularly those facing recurrent thrombotic issues and enduring a compromised quality of life, liver transplantation may offer a crucial, life-saving option. Moving forward, we believe it's essential to weigh the transplantation benefits against the potential risks while focusing on enhancing the patients' long-term quality of life.
Our focus was on an eight-year-old girl who had struggled with this deficiency since birth, enduring various treatments that failed to improve her health significantly. Despite receiving fresh frozen plasma transfusions and anticoagulants, she continued to experience severe complications and a poor quality of life.
Upon receiving care in the United Arab Emirates, she was placed on the national transplant waiting list for a liver transplant, which eventually took place successfully. Notably, after the surgery, her protein C activity normalized, and she did not experience any thrombotic events.
This case highlights that for children with homozygous protein C deficiency, particularly those facing recurrent thrombotic issues and enduring a compromised quality of life, liver transplantation may offer a crucial, life-saving option. Moving forward, we believe it's essential to weigh the transplantation benefits against the potential risks while focusing on enhancing the patients' long-term quality of life.
Read More
9
Flavonoids show potential against HBV
We investigated the effects of flavonoids derived from Andrographis paniculata on hepatitis B virus (HBV) replication and liver cancer progression. This study aimed to find a natural treatment alternative, especially considering the current drugs like HIV reverse transcriptase inhibitors can have severe side effects and come at a high cost.
Our research involved a series of tests, including checking how these compounds affected the virus in liver cells and their potential to reduce the virus's presence. We also examined the compounds' ability to influence key interactions within the HBV's protein machinery and evaluated their cytotoxicity levels.
The results were encouraging. We found that Andrographis paniculata showed lower toxicity compared to other treatments, and it effectively reduced HBV levels and inhibited the secretion of important viral markers. This suggests that the flavonoids may help disrupt the virus replication cycle and could be a promising candidate for developing new liver disease therapies.
With these findings, we have strong evidence indicating that natural compounds like those in Andrographis paniculata could pave the way for safer and more effective treatments for liver-related diseases.
Our research involved a series of tests, including checking how these compounds affected the virus in liver cells and their potential to reduce the virus's presence. We also examined the compounds' ability to influence key interactions within the HBV's protein machinery and evaluated their cytotoxicity levels.
The results were encouraging. We found that Andrographis paniculata showed lower toxicity compared to other treatments, and it effectively reduced HBV levels and inhibited the secretion of important viral markers. This suggests that the flavonoids may help disrupt the virus replication cycle and could be a promising candidate for developing new liver disease therapies.
With these findings, we have strong evidence indicating that natural compounds like those in Andrographis paniculata could pave the way for safer and more effective treatments for liver-related diseases.
Read More
9
We explored how andrographolide (AP), a natural compound known for its anti-inflammatory properties, impacts acute liver injury during sepsis. The study examined the pathways involved in liver injury and highlighted the role of a specific protein called FKBP1A.
Our findings indicate that AP can effectively promote FKBP1A expression, while at the same time reducing the harmful effects of another protein known as NOTCH1. We observed that when FKBP1A levels were increased, liver injury caused by sepsis was significantly reduced in mice, and the compound also protected liver cells from damage in lab settings.
However, if FKBP1A was knocked down, the protective effects of AP diminished. Interestingly, another treatment, dexamethasone, showed benefits related to NOTCH1, but not FKBP1A. This suggests that the mechanisms differ between treatments. By inhibiting NOTCH1 signaling, FKBP1A helps limit endoplasmic reticulum stress in liver cells, offering a valuable insight into how AP could be an effective therapy for liver injuries linked to sepsis.
Our findings indicate that AP can effectively promote FKBP1A expression, while at the same time reducing the harmful effects of another protein known as NOTCH1. We observed that when FKBP1A levels were increased, liver injury caused by sepsis was significantly reduced in mice, and the compound also protected liver cells from damage in lab settings.
However, if FKBP1A was knocked down, the protective effects of AP diminished. Interestingly, another treatment, dexamethasone, showed benefits related to NOTCH1, but not FKBP1A. This suggests that the mechanisms differ between treatments. By inhibiting NOTCH1 signaling, FKBP1A helps limit endoplasmic reticulum stress in liver cells, offering a valuable insight into how AP could be an effective therapy for liver injuries linked to sepsis.
Read More
9
We assessed the effects of inhibiting a protein known as MALT1 on a rare liver condition called hepatic sinusoidal obstruction syndrome (HSOS). This condition can be particularly risky for patients undergoing chemotherapy or stem cell transplants.
To understand its role, we used two mouse models and several types of cultured cells to analyze how the MALT1 inhibitor, MI-2, affects inflammation and liver damage. Our findings showed that MI-2 significantly reduced symptoms of HSOS in both models, such as the blockage of liver blood vessels and associated inflammatory responses.
Notably, treatment with MI-2 lowered levels of important markers linked to liver damage and inflammation. Further experiments revealed that this protein inhibitor not only mitigated the harmful effects of chemotherapy on liver tissue but also decreased oxidative stress—a major factor in inflammation. Overall, our findings suggest that targeting MALT1 could be a promising strategy for treating HSOS and its associated complications.
To understand its role, we used two mouse models and several types of cultured cells to analyze how the MALT1 inhibitor, MI-2, affects inflammation and liver damage. Our findings showed that MI-2 significantly reduced symptoms of HSOS in both models, such as the blockage of liver blood vessels and associated inflammatory responses.
Notably, treatment with MI-2 lowered levels of important markers linked to liver damage and inflammation. Further experiments revealed that this protein inhibitor not only mitigated the harmful effects of chemotherapy on liver tissue but also decreased oxidative stress—a major factor in inflammation. Overall, our findings suggest that targeting MALT1 could be a promising strategy for treating HSOS and its associated complications.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Taste and health benefits
9 people found this helpful
I bought this oil for salads, and it’s simply delightful! I didn’t expect it to be so tasty. I often change my salad oils, but this one is exceptionally pleasant. It sits lightly on my stomach and feels curative for my liver and pancreas. I'm keen to order it regularly. Compared to olive oil, which feels heavy, this oil is rich yet light. I can’t quite describe my feelings otherwise.
Read More
2
No benefits observed
Its smell is unpleasant, and the texture feels stinging on my liver, and I didn’t observe any benefits from it, even after two days of use.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Patil VS, Harish DR, Charla R, Bhandare VV, Gujarathi SS, et al. Flavonoids of Andrographis paniculata regulate hepatitis B virus replication and hepatocellular carcinoma progression: evidence from computational and experimental studies. BMC Complement Med Ther. 2025;25:95. 10.1186/s12906-025-04807-z
- Ye T, Wu Z, Liu X, Wu J, Fu Q, et al. Engineered mesenchymal stromal cells with bispecific polyvalent peptides suppress excessive neutrophil infiltration and boost therapy. Sci Adv. 2025;11:eadt7387. 10.1126/sciadv.adt7387
- He J, Huang Z, Zou R. Andrographolide ameliorates sepsis-induced acute liver injury by attenuating endoplasmic reticulum stress through the FKBP1A-mediated NOTCH1/AK2 pathway. Cell Biol Toxicol. 2025;41:56. 10.1007/s10565-025-10007-9
- Sharma N, Chandra Y, Andugulapati SB. Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF-κB Pathway. Liver Int. 2025;45:e70050. 10.1111/liv.70050
- Outla Z, Oyman-Eyrilmez G, Korelova K, Prechova M, Frick L, et al. Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis. Elife. 2025;13. 10.7554/eLife.102205
- Syed Iqbaluddin J, Asif Amin S, Fawzy Nazir Abouelkhel H, Shaji Mathew J, Sen G, et al. Liver Transplantation as a Definitive Treatment for Homozygous Protein C Deficiency. Cureus. 2025;17:e78498. 10.7759/cureus.78498
- Zheng X, Tian S, Li T, Zhang S, Zhou X, et al. Host FSTL1 defines the impact of stem cell therapy on liver fibrosis by potentiating the early recruitment of inflammatory macrophages. Signal Transduct Target Ther. 2025;10:81. 10.1038/s41392-025-02162-6
- Hua S, Zhong W, Sha Y, Ma M, Ge S. Negative association of composite dietary antioxidant index with risk of hepatic fibrosis in individuals underwent cholecystectomy: a cross-sectional study. Sci Rep. 2025;15:9040. 10.1038/s41598-025-93782-z
- Song Y, Ni W, Zheng M, Sheng H, Wang J, et al. Vitamin E (300Â mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell Rep Med. 2025;6:101939. 10.1016/j.xcrm.2025.101939
- Palencia-Campos A, Ruiz-Cañas L, Abal-Sanisidro M, López-Gil JC, Batres-Ramos S, et al. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. J Nanobiotechnology. 2024;22:795. 10.1186/s12951-024-03010-5
- Dong JX, Jiang LL, Liu YP, Zheng AX. Association between composite dietary antioxidant index and metabolic dysfunction-associated fatty liver disease: a cross-sectional study from NHANES. BMC Gastroenterol. 2024;24:465. 10.1186/s12876-024-03556-6
- Sahin A, Demirel-Yalciner T, Sozen E, Ozer NK. Protective effect of alpha-tocopherol on lipogenesis and oxysterol production in hypercholesterolemia-induced nonalcoholic steatohepatitis. Free Radic Res. 2024;58:630. 10.1080/10715762.2024.2421173
- Wen H, Deng H, Yang L, Li L, Lin J, et al. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2024;10:CD015033. 10.1002/14651858.CD015033.pub2
- Adly AAM, Ismail EAR, Ibrahim FA, Atef M, El Sayed KA, et al. A 6-month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications. J Inherit Metab Dis. 2025;48:e12792. 10.1002/jimd.12792
- Al-Baiaty FDR, Ishak S, Mohd Zaki F, Masra F, Abdul Aziz DA, et al. Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial. BMC Pediatr. 2024;24:529. 10.1186/s12887-024-04993-8
- Chee NM, Sinnanaidu RP, Chan WK. Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2024;39:2545. 10.1111/jgh.16723
- Li J, Yang Y, Huang J, Ye D, Sun X, et al. A Comprehensive Investigation of Dietary Micronutrient Intakes and Risk of Alcoholic Liver Disease. J Nutr. 2024;154:2909. 10.1016/j.tjnut.2024.07.012
- Wang X, Liang X, Zhang N, Wang Y, Hu M, et al. Gamma-tocotrienol Inhibits Proliferation and Growth of HSD17B4 Overexpressing HepG2 Liver Cancer Cells. Curr Cancer Drug Targets. 2025;25:170. 10.2174/0115680096319171240623091614
- Albert SG, Wood EM. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD). J Diabetes Complications. 2024;38:108777. 10.1016/j.jdiacomp.2024.108777
- Akman AU, Erisgin Z, Turedi S, Tekelioglu Y. Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric research. Clin Exp Hepatol. 2023;9:359. 10.5114/ceh.2023.132251
- Malandris K, Papandreou S, Vasilakou D, Kakotrichi P, Sarakapina A, et al. Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis. J Gastroenterol Hepatol. 2024;39:1219. 10.1111/jgh.16559
